Breast最新文献

{"title":"Raising awareness of alcohol as a modifiable risk factor for breast cancer: A randomized controlled trial comparing the efficacy of accessing an interactive website with a non-interactive website","authors":"Claudia Sardu ,&nbsp;Fabrizio Angius ,&nbsp;Paolo Contu ,&nbsp;Sofia Cosentino ,&nbsp;Monica Deiana ,&nbsp;Matteo Fraschini ,&nbsp;Clelia Madeddu ,&nbsp;Elena Massa ,&nbsp;Alessandra Mereu ,&nbsp;Luigi Minerba ,&nbsp;Carola Politi ,&nbsp;Silvia Puxeddu ,&nbsp;Francesco Salis ,&nbsp;Julia M.A. Sinclair ,&nbsp;Roberta Agabio","doi":"10.1016/j.breast.2024.103868","DOIUrl":"10.1016/j.breast.2024.103868","url":null,"abstract":"<div><h3>Background</h3><div>Alcohol consumption is a potentially modifiable risk factor for breast cancer (BC). Reducing alcohol consumption within the daily amount at low-risk for alcohol-related consequences (daily alcohol threshold) may contribute to preventing BC new cases. However, most women are unaware of risk factors for BC, the daily alcohol threshold, and how to measure alcohol use. We aimed at investigating the efficacy of accessing an interactive website in increasing the knowledge that alcohol is a BC risk factor.</div></div><div><h3>Methods</h3><div>We conducted a randomized controlled trial among women waiting for mammography. Women completed a questionnaire to investigate their knowledge before and after accessing an interactive (intervention group) and non-interactive (control group) website.</div></div><div><h3>Results</h3><div>We recruited 671 women, randomized 329 (49.0 %) and 342 (51.0 %) to the intervention and control groups, respectively. At baseline, most women were not aware of most modifiable BC risk factors. Accessing either website significantly increased the percentage of women who acquired the knowledge on BC risk factors, with the interactive website achieving better results: 82 % and 69 % of women acquired the knowledge that alcohol is a risk factor for BC in the intervention and control groups, respectively (p &lt; 0.001). Among women with lower levels of education, the probability of acquiring this knowledge was higher in the intervention group than control group.</div></div><div><h3>Conclusion</h3><div>Our results show that accessing an interactive website may increase the percentage of women who acquire the knowledge that alcohol is a BC risk factor especially among women of lower levels of education.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103868"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric validation of the Danish BREAST-Q reconstruction module","authors":"Cecilie Balslev Willert ,&nbsp;Karl Bang Christensen ,&nbsp;Pernille Envold Bidstrup ,&nbsp;Lene Mellemkjær ,&nbsp;Anne-Marie Axø Gerdes ,&nbsp;Lisbet Rosenkrantz Hölmich","doi":"10.1016/j.breast.2025.103872","DOIUrl":"10.1016/j.breast.2025.103872","url":null,"abstract":"<div><h3>Aim/background</h3><div>Patient-reported outcome measurement instruments are important tools in understanding a breast reconstruction's impact on the patients' quality of life. A psychometric validation is essential before applying a patient-reported outcome measurement instrument in clinical practice and research. The BREAST-Q is a specific, validated questionnaire for breast surgery outcomes that has been translated from English to Danish. It consists of 167 items in 7 pre-operative scales and 15 post-operative scales. This validation study aims to validate the Danish BREAST-Q reconstruction module.</div></div><div><h3>Material and methods</h3><div>Eligible women were included from January 2019 to June 2020. Multiple-item scales with summated scores and more than 40 complete responses were eligible for psychometric validation, and psychometric analyses examined reliability and validity using Rasch Analyses and Classical Test Theory. Measurements included test for local response dependence, item fit, differential item functioning, and more. Clinical validity was assessed using known-groups hypotheses.</div></div><div><h3>Results</h3><div>We obtained 115 and 201 complete responses pre-and postoperatively, respectively. We validated 120 items in four preoperative and nine postoperative scales. The Rasch analyses disclosed evidence of local response dependence in eight scales. Chronbach's α ranged 0.81–0.95 after adjustment. Item fit was evaluated using item-restscore correlations and showed good fit in 98 % of items. Differential Item Functioning was found in four items but had very little effect on the model. Clinical validity was supported by the know-group analyses.</div></div><div><h3>Discussion/conclusion</h3><div>The Danish BREAST-Q reconstruction module has good acceptability, feasibility and validity, and adequate reliability. The results support the use in a Danish population.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103872"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting","authors":"Erik Olsson ,&nbsp;Henrik Lindman ,&nbsp;Evangelos Digkas ,&nbsp;Viktoria Thurfjell ,&nbsp;Haidar Mir Ali ,&nbsp;Ute Krüger ,&nbsp;Anna-Karin Wennstig ,&nbsp;Marie Sundqvist ,&nbsp;Antonios Valachis","doi":"10.1016/j.breast.2025.103874","DOIUrl":"10.1016/j.breast.2025.103874","url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting.</div></div><div><h3>Patients and methods</h3><div>Next-generation sequencing with FoundationOne® CDx was conducted primarily on primary tumor tissue from 112 consecutive patients with mTNBC. Genomic alterations were subdivided into canonical oncogenic pathways and noted for their involvement in homologous recombination deficiency (HRD). Altered genes and pathways were correlated with overall survival (OS) and evaluated regarding their association with real-world progression-free survival (rwPFS) in patients treated with different chemotherapy agents. Occurrence of alterations were compared between patients with exceptional response and rapid progression to chemotherapy.</div></div><div><h3>Results</h3><div>After exclusion due to insufficient tumor tissue or clinical data, material from 97 patients was analyzed. The most frequently altered genes were TP53 (82 %), RAD21 (25 %) and PIK3CA (23 %). Altogether, 26 % of patients had an alteration leading to HRD. None of the analyzed alterations were associated with OS. Variants leading to HRD were associated with a prolonged rwPFS in patients treated with platinum-based chemotherapy in the first line setting (hazard ratio [HR], 0.31 [95 % CI: 0.12–0.84]). Exceptional responders more often exhibited alterations in the MYC and RAS/RTK pathways compared to rapid progressors.</div></div><div><h3>Conclusions</h3><div>Patients with tumor alterations in HRD-related genes seem to define subgroups that respond favorably to platinum-based chemotherapy. Further research into the genomic landscape of tumors from patients with rapid progression or exceptional response to different treatment strategies can provide insights into mechanisms of resistance and identify predictive biomarkers.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103874"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status","authors":"Xuxiazi Zou ,&nbsp;Hong-Liang Zou ,&nbsp;Xuan Luo ,&nbsp;Xu-Wei Chen ,&nbsp;Wei-Ling Huang ,&nbsp;Chao Zhang ,&nbsp;Ge Ren ,&nbsp;Jin-Hua Huang ,&nbsp;Xue Han ,&nbsp;Yi-Quan Jiang","doi":"10.1016/j.breast.2025.103876","DOIUrl":"10.1016/j.breast.2025.103876","url":null,"abstract":"<div><h3>Background</h3><div>Current decision-making for the treatment of breast cancer liver metastases (BCLM) using ablation lacks strong evidence, especially for patients combined with extrahepatic metastases.</div></div><div><h3>Purpose</h3><div>To assess whether ablation plus systemic therapy (AS) improves survival outcomes in patients with BCLM compared to systemic therapy alone.</div></div><div><h3>Materials and methods</h3><div>This retrospective study analyzed patients with BCLM who received either AS or systemic therapy alone. Propensity score matching (PSM) and survival analysis were performed, taking into account factors like the characteristics of primary breast cancer, liver metastases and systemic therapies received.</div></div><div><h3>Results</h3><div>The study included 1021 female patients, with a median follow-up of 39.6 months. Of these patients, 132 underwent AS and 836 received systemic therapy alone. After PSM, among patients with BCLM (≤3 tumors, each ≤3 cm), the median overall survival (OS) for those treated with AS or systemic therapy alone was 65.5 and 40.4 months, respectively (HR = 0.48, p = .003); in the subset of patients with extrahepatic metastases, the median OS for those treated with AS and systemic therapy alone was 46.4 and 40.8 months, respectively (HR = 0.58, p = .047). Among patients with &gt;3 cm or &gt;3 lesions, the median OS for those treated with AS or systemic therapy alone was 45.2 and 29 months, respectively (HR = 0.67, p = .084).</div></div><div><h3>Conclusions</h3><div>Among patients with BCLM (≤3 tumors, each ≤3 cm), AS provide longer survival compared to systemic therapy alone, even with extrahepatic metastases. For patients with larger or more numerous metastases (&gt;3 cm or &gt;3 lesions), AS may provide survival benefit, but further validation is needed.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103876"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic strategies for fungating and ulcerating breast cancers: A systematic review and narrative synthesis","authors":"Valentina Zagardo ,&nbsp;Mandara Harikar ,&nbsp;Gianluca Ferini","doi":"10.1016/j.breast.2024.103870","DOIUrl":"10.1016/j.breast.2024.103870","url":null,"abstract":"<div><h3>Background</h3><div>To identify optimal therapeutic strategies for managing fungating, large or ulcerating breast tumors and highlight existing gaps in the literature.</div></div><div><h3>Methods</h3><div>We conducted a systematic search of Medline, Embase, APA, PsycInfo, CAB abstracts, Scopus, and Web of Science from inception to June 30, 2024, including studies on patients with fungating, large, or ulcerating breast cancers.</div></div><div><h3>Results</h3><div>The search identified 7917 studies, with 79 meeting the inclusion criteria: 62 case reports, 7 case series, and 10 cohort studies. Owing to high heterogeneity, a narrative synthesis was performed, categorizing treatment by year, molecular subtype, histology, and staging. We found that treatment modalities increased, from an average of two in luminal-B cancers to three in HER2-positive cases, with over half achieving complete response. Triple-negative breast cancers averaged two modalities, with around half showing only partial response. Cohort analysis revealed a significant positive correlation between metastasis rate and radiotherapy use (Spearman's rho = 0.828, p = 0.042) and between chemotherapy and hormonal therapy use (rho = 0.69, p = 0.04). Median survival was positively correlated with surgical treatment (rho = 0.82, p = 0.046).</div></div><div><h3>Conclusions</h3><div>Local treatment is crucial for symptomatic palliation in fungating or ulcerating breast tumors, and histology should guide therapeutic choices. While local treatments remain primary, emerging systemic therapies show promise and may soon become first-line options. As the first systematic review on this topic, our study faced considerable source heterogeneity, precluding a meta-analysis. Instead, we analyzed treatment trends by demographics and tumor characteristics, providing a comprehensive overview and encouraging further research in this area.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103870"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact on productivity costs of reducing unemployment in patients with advanced breast cancer: A model estimation based on a Portuguese nationwide observational study","authors":"Leonor Vasconcelos de Matos ,&nbsp;Margarida Borges ,&nbsp;Ana Teresa Oliveira ,&nbsp;Carolina Bulhosa ,&nbsp;Luís Silva Miguel ,&nbsp;Tiago Fidalgo de Freitas ,&nbsp;Renato Cunha ,&nbsp;Ana Duarte Mendes ,&nbsp;Ana Júlia Arede ,&nbsp;Cristiana Marques ,&nbsp;Diogo Alpuim Costa ,&nbsp;Jorge Alves Correia ,&nbsp;Margarida Brito ,&nbsp;Mário Fontes e Sousa ,&nbsp;Teresa Guimarães ,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2024.103867","DOIUrl":"10.1016/j.breast.2024.103867","url":null,"abstract":"<div><div>This study aimed to characterize the employment status and work-related conditions of patients with advanced breast cancer (ABC) in Portugal and quantify the productivity costs of premature abandonment of the work market while evaluating strategies to promote employment. The analysis was based on a cumulative incidence model for estimation of ABC prevalence and on a cross-sectional study characterizing the employment status of patients with ABC. This study was conducted in Portuguese hospitals, between Nov2021-Dec2022 and included patients diagnosed with ABC for at least 6 months, aged 66 or less and consenting for a self-answered questionnaire regarding work status. A total of 2151 working-aged women were estimated to have ABC in 2019 in Portugal, with productivity costs amounting to 28,676,754€ over 2019–2021. 112 patients from 9 hospitals were included in the study, average age was 52yr, 48 % had a postsecondary educational degree level and 87 % reported having a paid job at the time of diagnosis, mostly full-time. At the time of the study, only 38 % of the patients maintained the job status. The remaining were unemployed (51 %), on medical leave (25 %) or retired (24 %). Stop working was a personal choice for only 5 %. A subsidized part-time employment regimen, despite increased government costs, would allow a reduction in productivity costs, leading to a positive balance of 2,431,329€ over the same period. This study suggests that the majority of patients with ABC abandon the labor market before the age of retirement. Flexible work arrangements would benefit the patient, the government and the society. ‘</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103867"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is preoperative imaging of sentinel lymph node in breast cancer necessary? A retrospective case control study","authors":"Michael J. Reinhardt ,&nbsp;Björn Ohmstede ,&nbsp;Luz Angela Torres-de la Roche ,&nbsp;Rudy Leon De Wilde","doi":"10.1016/j.breast.2024.103856","DOIUrl":"10.1016/j.breast.2024.103856","url":null,"abstract":"<div><h3>Objective</h3><div>The necessity of preoperative lymphoscintigraphy before intraoperative sentinel lymph node (SLN) identification is still unclear. The aim of the present study was to evaluate the impact of SLN imaging on intraoperative SLN detection in breast cancer patients.</div></div><div><h3>Methods</h3><div>Retrospective, comparative, single center study of patients with breast cancer stage pT1 and pT2 who underwent axillary staging. Group 1 included patients who underwent SLN extirpation without preoperative SLN imaging, and Group 2 included patients who underwent SLN imaging prior to surgery. Differences between groups were analyzed using T-test and chi-square test.</div></div><div><h3>Results</h3><div>926 (mean age: 61.45 years) patients received subdermal injection of radiolabeled nanocolloids between tumor and axilla. SLN was identified intraoperatively in 473 of 498 patients (94.98 %) in group 1, and in 415 of 428 patients (96.96 %) in group 2 (p = 0.129). Lymphoscintigraphy detected SLN in 407 of 428 (95.09 %) patients in group 2. Due to the additional SLN imaging in group 2, the time between radiotracer injection and start of surgery was significantly prolonged (p &lt; 0.001). A reduction of applied activity from a median of 18 MBq in group 1 to a median of 12 MBq in group 2 had no negative effect on the SLN identification.</div></div><div><h3>Conclusion</h3><div>Subdermal injection of radiolabeled nanocolloids between tumor and axilla allowed high intraoperative detection of SLN. Preoperative SLN imaging had no significant impact on the intraoperative detection but is a time-consuming and resource-intensive procedure. Prospective studies might provide further evidence to omit preoperative SLN imaging in patients with T1-2 invasive breast cancer and clinically negative axilla.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103856"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal data integration in early-stage breast cancer","authors":"Arnau Llinas-Bertran ,&nbsp;Maria Butjosa-Espín ,&nbsp;Vittoria Barberi ,&nbsp;Jose A. Seoane","doi":"10.1016/j.breast.2025.103892","DOIUrl":"10.1016/j.breast.2025.103892","url":null,"abstract":"<div><div>The use of biomarkers in breast cancer has significantly improved patient outcomes through targeted therapies, such as hormone therapy anti-Her2 therapy and CDK4/6 or PARP inhibitors. However, existing knowledge does not fully encompass the diverse nature of breast cancer, particularly in triple-negative tumors.</div><div>The integration of multi-omics and multimodal data has the potential to provide new insights into biological processes, to improve breast cancer patient stratification, enhance prognosis and response prediction, and identify new biomarkers.</div><div>This review presents a comprehensive overview of the state-of-the-art multimodal (including molecular and image) data integration algorithms developed and with applicability to breast cancer stratification, prognosis, or biomarker identification. We examined the primary challenges and opportunities of these multimodal data integration algorithms, including their advantages, limitations, and critical considerations for future research. We aimed to describe models that are not only academically and preclinically relevant, but also applicable to clinical settings.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103892"},"PeriodicalIF":5.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter: What can paintings teach us?","authors":"Serena Di Cosimo, Antonio Perciaccante, Simon T Donell, Judith Wimmer, Andreas G Nerlich, Johann C DeWaal, Laura Cortesi, Raffaella Bianucci","doi":"10.1016/j.breast.2025.103893","DOIUrl":"https://doi.org/10.1016/j.breast.2025.103893","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"103893"},"PeriodicalIF":5.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42","authors":"Vesna Bjelic-Radisic ,&nbsp;Fatima Cardoso ,&nbsp;Joachim Weis ,&nbsp;Katarzyna Pogoda ,&nbsp;Juan Ignacio Arraras ,&nbsp;Elfriede Greimel ,&nbsp;Andrew Bottomley ,&nbsp;David Cameron ,&nbsp;Etienne Brain ,&nbsp;Sue Hartup ,&nbsp;Rene Alosio Da Costa Vieira ,&nbsp;Nicolette Hoefnagels ,&nbsp;Chi Shen Huang ,&nbsp;Omar Shamieh ,&nbsp;Monica Pinto ,&nbsp;Yarad Belete Belay ,&nbsp;Samantha Serpentini ,&nbsp;Eveline Bleiker ,&nbsp;Manjunath Nookala ,&nbsp;Akira Shimomura ,&nbsp;Galina Velikova","doi":"10.1016/j.breast.2025.103890","DOIUrl":"10.1016/j.breast.2025.103890","url":null,"abstract":"<div><h3>Background</h3><div>The EORTC QLQ-BR23, published in 1996, was one of the first disease-specific questionnaires to assess health-related quality of life (HRQoL) in patients with breast cancer (BC). In the last decades, major changes in BC treatment have occurred, requiring an update of this module. The results of the Phase 1–3 of the study were published in 2019. The aim of study was to examine the psychometric properties of the provisional EORTC-QLQ-BR45.questionnaire.</div></div><div><h3>Methods</h3><div>Patients with a diagnosis of BC, age ≥18 years, and cognitive able to fill the questionnaire were included in the study and completed the provisional questionnaire during a visit at each participating centre. Psychometric analyses included the evaluation of the scale structure, internal consistency, test-retest reliability, convergent, discriminant, and clinical validity, and responsiveness to change.</div></div><div><h3>Results</h3><div>Between May 2019 and September 2021, 576 patients from 22 centers (17 countries, 16 languages) were enrolled in the study. The psychometric analyses resulted in a final questionnaire containing 42 items divided into 10 scales: Breast Symptoms, Body Image, Sexual Functioning, Arm Symptoms, Systemic Chemotherapy Side Effects, Hand/Feet Symptoms/Neuropathy, Skeletal Symptoms, Endocrine Symptoms, Breast Satisfaction, Vaginal Symptoms, and 3 single items: Weight Gain, Sexual Enjoyment and Future Perspective.</div></div><div><h3>Conclusion</h3><div>The revised EORTC QLQ-BR42 questionnaire incorporates the EORTC-QLQ-BR23 original items, combined with 19 new items that address the new therapies developed over the past 20 years. This comprehensive module is a valid instrument to assess the HRQoL of BC patients and can be used in place of the BR23 in future trials.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103890"},"PeriodicalIF":5.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}